Risk analysis for outpatient experimental infection as a pathway for affordable RSV vaccine development. - Siegal EZ; Schoevers JMH; Terstappen J; Delemarre EM; Johnston SL; van Beek LF; Bogaert D; Chiu C; Diavatopoulos DA; Ferreira DM; Gordon SB; Hayden FG; et al. (NPJ vaccines, 2025)